MedPath

Cutaneous Microcirculation After Plasma Therapy

Not Applicable
Completed
Conditions
Acute Wound
Burn Scar
Burn Injury
Chronic Wound
Registration Number
NCT02417818
Lead Sponsor
University Hospital Schleswig-Holstein
Brief Summary

In plastic and reconstructive surgery, treatment strategies of second-degree burns, superficial wounds, burn scars, flaps and chronic wounds aim at reducing infection and improving microcirculation. Although previous studies indicate that Plasma Therapy can accelerate wound healing, only a few studies focused on the elucidation of its mechanisms of action. Therefore, the aim of this study is to evaluate the microcirculatory effects of Plasma Therapy on second-degree burns, superficial wounds, burn scars, flaps and chronic wounds in a human in-vivo setting for the first time.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
240
Inclusion Criteria

Group A (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.

Group B (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of TBSA.

Group C (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.

Group D (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident. No soft tissue injury must be evident.

Group E (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.

Group F (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of TBSA.

Group G (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.

Group H (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups E-G must be evident. No soft tissue injury must be evident.

Group I (n=20): Consent-capable male and female patients ≥18 years of age suffering from a hypertrophic burn wound.

Group J (n=20): Consent-capable male and female patients ≥18 years of age suffering from a hypertrophic burn wound.

Group K (n=20): Consent-capable male and female patients ≥18 years of age received a flap.

Group L (n=20): Consent-capable male and female patients ≥18 years of age received a flap.

Exclusion Criteria

General exclusion criteria

  • below 18 years of age
  • wounds requiring artificial respiration, since consent for the study participation is unobtainable

Exclusion criteria groups A, B, D, E, F, H:

  • peripheral arterial occlusive disease
  • vasculitis
  • diabetes mellitus
  • chronic kidney or liver disease
  • cardiac dysfunction
  • arterial hypo- or hypertension

Anamnestic exclusion criteria

  • ongoing immunosuppressive or chemotherapy treatment
  • drug abuse
  • systemic skin diseases
  • systemic and local cortisone therapy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Change in microcirculation (composite measure)Baseline and 1 minute post-dose

* capillary blood flow \[arbitrary units AU\]

* capillary blood velocity \[AU\]

* tissue oxygen saturation \[%\]

* relative postcapillary venous filling pressure \[AU\]

Secondary Outcome Measures
NameTimeMethod
Change in microcirculation (areolar measure)Baseline, while and 1 minute post-dose

* tissue oxygen saturation \[%\]

* tissue hemoglobin index

Trial Locations

Locations (1)

University of Schleswig-Holstein

🇩🇪

Lübeck, Schleswig-Holstein, Germany

University of Schleswig-Holstein
🇩🇪Lübeck, Schleswig-Holstein, Germany

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.